Neoadjuvant Opdivo with chemotherapy significantly improves overall survival in resectable NSCLC compared to chemotherapy alone, as shown in the CheckMate-816 study. The study's primary endpoints, ...
The addition of atezolizumab to standard neoadjuvant chemotherapy followed by adjuvant atezolizumab did not significantly improve event-free survival (EFS) in patients with stages II-III ...
Please provide your email address to receive an email when new articles are posted on . Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across ...
Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.
Tyvyt plus CRT achieved a 60% pCR rate, outperforming Tyvyt plus chemotherapy (13%) and CRT alone (47.3%). Neoadjuvant Tyvyt plus CRT may become a new standard of care for resectable, locally advanced ...
We would like to comment on Schuler et al., on their well-designed randomized phase II NEOpredict-Lung study (NCT04205552) which was published in Nature Medicine. The main objective of this study was ...
The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing surgery alone to neoadjuvant chemotherapy with or without immunotherapy.
Neoadjuvant immunotherapy could considerably improve long-term outcomes and quality of life for patients with desmoplastic melanoma, according to prospective study results.Nearly three-quarters of ...
Nonresponders to UTUC neoadjuvant chemo have more aggressive recurrence patterns that may have important surveillance and treatment implications. Patients with node-positive disease after neoadjuvant ...
Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results